Status:
COMPLETED
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer: Continued Avastin Plus Chemotherapy After First Progression in Clinical Practice
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This local, non-interventional, cohort study of patients with metastatic colorectal cancer (mCRC) will prospectively collect data from standard clinical practice of second-line treatment with chemothe...
Eligibility Criteria
Inclusion
- Written informed consent
- Age \>/=18 years
- Metastatic colorectal cancer (mCRC) previously treated with systemic treatment for advanced disease containing Avastin and chemotherapy; first-line Avastin received according to the Summary of Product Characteristics (SmPC)
- First line progression-free survival (PFS) \>6 months
- Eligible for second-line chemotherapy regimen
- Period between first progression and start of second line treatment with Avastin and chemotherapy \</=6 weeks
Exclusion
- Contraindications, warnings and precautions for use specified in the Avastin SmPC
Key Trial Info
Start Date :
November 13 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 21 2018
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT02287597
Start Date
November 13 2014
End Date
March 21 2018
Last Update
July 30 2018
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Hospital Osijek; Dept For Oncology & Radiotherapy
Osijek, Croatia, 31000
2
Uni Hospital Split; Oncology & Radiotherapy
Split, Croatia, 21000
3
Clinical Hospital Centre Zagreb
Zagreb, Croatia, 10000
4
Uni Hospital For Tumours; Dept of Medical Oncology
Zagreb, Croatia, 10000